UM  > 健康科學學院
Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China
Hou C.-L.6; Ma X.-R.3; Zang Y.8; Jia F.-J.6; Lin Y.-Q.6; Chiu H.F.K.7; Ungvari G.S.5; Ng C.H.4; Zhong B.-L.7; Cao X.-L.8; Li Y.7; Cai M.-Y.2; Xiang Y.-T.9
2016
Source PublicationInternational Journal of Clinical Pharmacology and Therapeutics
ISSN09461965
Volume54Issue:1Pages:36-42
Abstract

Objective: In China, maintenance treatment for clinically stable patients with schizophrenia is usually provided by primary care physicians, but their prescribing patterns have not been studied. This study examined the frequency as well as demographic and clinical correlates of antipsychotic polypharmacy (APP) and its impact on quality of life (QOL) in patients with schizophrenia treated in primary care in China. Method: A total of 623 community-dwelling patients from 18 randomly selected primary care services were interviewed. Patients' socio-demographic and clinical characteristics, including number of hospitalizations, antipsychotic drug-induced side effects, and QOL were recorded using a standardized protocol and data collection procedure. Results: The rate of APP prescription was 31% (193/623). Of the patients on APP, 89.6% received 2 antipsychotics, 10.4% received 3 or more antipsychotics. Clozapine (35.6%) was the most commonly prescribed second generation antipsychotic (SGA), while perphenazine (17.8%) was the most commonly prescribed first generation antipsychotic (FGA). Multiple logistic regression analyses revealed that patients on APP were more likely to receive SGAs and anticholinergics, had fewer hospitalizations, younger age of onset, and higher doses of antipsychotics. There were no significant differences between the two groups in any of the QOL domains. Conclusions: Approximately a third of Chinese patients with schizophrenia in primary care receive APP. Further examination of the rationale and appropriateness of APP and its alternatives is warranted.

KeywordAntipsychotic Polypharmacy China Community-dwelling Schizophrenia
DOI10.5414/CP202413
URLView the original
Indexed BySCI
Language英语
WOS Research AreaPharmacology & Pharmacy
WOS SubjectPharmacology & Pharmacy
WOS IDWOS:000369882400005
Fulltext Access
Citation statistics
Cited Times [WOS]:9   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Affiliation1.Ningxia Ning-An Hospital
2.Guangdong Center for Disease Control and Prevention
3.Southern Medical University
4.University of Melbourne
5.University of Western Australia
6.Guangdong General Hospital
7.Chinese University of Hong Kong
8.Shenzhen Institute of Mental Health and Shenzhen Kangning Hospital
9.Universidade de Macau
Recommended Citation
GB/T 7714
Hou C.-L.,Ma X.-R.,Zang Y.,et al. Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China[J]. International Journal of Clinical Pharmacology and Therapeutics,2016,54(1):36-42.
APA Hou C.-L..,Ma X.-R..,Zang Y..,Jia F.-J..,Lin Y.-Q..,...&Xiang Y.-T..(2016).Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China.International Journal of Clinical Pharmacology and Therapeutics,54(1),36-42.
MLA Hou C.-L.,et al."Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China".International Journal of Clinical Pharmacology and Therapeutics 54.1(2016):36-42.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Hou C.-L.]'s Articles
[Ma X.-R.]'s Articles
[Zang Y.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Hou C.-L.]'s Articles
[Ma X.-R.]'s Articles
[Zang Y.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Hou C.-L.]'s Articles
[Ma X.-R.]'s Articles
[Zang Y.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.